7 cardiologists and leaders of cardiology service lines discuss the essential clinical developments that are enhancing heart care.
Editors note: Responses have been edited for clarity and length and are provided alphabetically.
Concern: What is the most appealing scientific development in cardiology today?
Kimberly Bell, vice president of Altamonte Springs, Fla.-based AdventHealth Cardiovascular Institute
From the AdventHealth Cardiovascular Institute viewpoint, the most promising scientific developments in cardiology today consist of:
. There have been lots of amazing innovations in the field of cardiology over the last couple of years. One specific development that calls for highlighting is a newer class of drugs called sodium-glucose transport protein 2 inhibitors (SGLT-2 inhibitors) for Type 2 diabetes.
Sanjeev Gulati, MD, chief of adult cardiology and medical director of heart failure and transplant services at Atrium Healths Sanger Heart & & Vascular Institute in Charlotte, N.C
These emerging wearable innovations will hopefully reduce the expense of care and translate into better medical results, as they can be implemented among populations rather than people. Combined with constant tracking, virtual care brings remarkable value to the patient, due to the fact that the proper healthcare decisions can be made as the need occurs.
Gopi Dandamudi, MD, medical director of Tacoma, Wash.-based CHI Franciscans cardiovascular service line
The capability to offer on-demand clinical appointments to clients practically on a big scale and the ability to monitor clients in genuine time on a continuous basis using wearable innovations are two of the most promising clinical innovations in cardiology today. With the introduction of COVID-19 and the need for social distancing, these two innovations have allowed us to continue to deliver care to our most susceptible patients by keeping them in familiar surroundings while continuing to provide access to prompt care.
This class of drugs is really an advancement in how we look after cardiovascular clients due to the fact that these are diabetic medications which are being utilized in cardiovascular clients without diabetes for their cardiovascular advantages. This class of medications is now an integral part of the cardiologists tool box to enhance cardiovascular outcomes.
● Wireless iFR (cordless evaluation of stenotic CAD) ● TAVR for aortic stenosis and aortic deficiency ● Robotic LIMA to LAD (left internal mammary artery to left anterior coming down artery) ● Leadless AICD (implantable defibrillator) ● Renal artery denervation for hypertension ● Shock wave treatment for treatment for peripheral arterial illness and coronary artery disease
In patients with HFrEF (EF less than 40 percent) with or without diabetes, dapagliflozin lowered cardiovascular deaths and cardiac arrest hospitalizations when compared to a placebo. For this reason, the suggestion is to include dapagliflozin for patients with HFrEF and NYHA class II-IV symptoms on optimum pharmacologic and device treatment. In addition, SGLT-2 inhibitors have been shown to minimize risks of cardiac arrest occasions in clients with Type 2 diabetes mellitus at high threat for or with heart disease.
David Kanzari, MD, chief of Atlanta-based Piedmont Heart Institute and the cardiovascular service line
Similarly crucial, the less invasive method of TAVR forged a path of development and exploration for catheter-based treatments to treat other heart valve conditions, such as tricuspid and mitral valve illness. All together, TAVR has actually used a less-invasive, lifesaving treatment and presented a new standard of care for patients with valvular heart illness.
The most appealing forthcoming technology in cardiovascular medication is catheter-based kidney denervation treatment. High blood pressure is the leading worldwide cause of death and special needs. In spite of increasing awareness of the effect of more extensive blood pressure lowering, rates of treatment and accomplishment of guideline-recommended blood pressure objectives have actually plateaued, if not steadily decreased. Additionally, it is estimated that at least one-third of patients dealt with for hypertension do not stick to their proposed medical regimen. These findings underscore the chance for alternative healing methods to high blood pressure. Renal denervation treatment has been regularly shown to safely reduce high blood pressure amongst individuals with constantly raised blood pressure, both in the existence and absence of pharmaceutical therapies. As such, the treatment is poised to have substantial global effect on public health.
Scott Lim, MD, medical director of the Advanced Cardiac Valve Center at UVA Healths Heart and Vascular Center in Charlottesville
For patients with cardiac arrest related to a weakness of their hearts ability to pump blood forward, the Accucinch device is being studied as a gadget to improve their hearts strength. It is a band placed on the inside of the heart to improve the heart into a shape that is more powerful. It is being studied in a randomized medical trial, and early information from the feasibility trial was motivating.
Lisa Marteney-Mock, Registered Nurse, interim executive director of cardiovascular services at Beebe Healthcare in Lewes, Del
All together, TAVR has used a less-invasive, lifesaving treatment and presented a brand-new standard of care for patients with valvular heart disease.
. There are many technological developments in cardiology today, however one that has really made an impact at Beebe Healthcare is the access to minimally invasive technology like the transcatheter aortic valve replacement treatment. We are a 210-bed health center in Lewes, Del., that serves a rural population that sees an increase of visitors in the summertime. Now our neighborhood has the choice for this ingenious treatment as an alternative to open heart surgical treatment that is close to house and enables them to return house the next day. When their community health system can use this these developments, that produces in general better health care for a neighborhood.
Hal Skopicki, MD, chief of cardiology and co-director of the Stony Brook (N.Y.) University Heart Institute
Current analyses of modern medical research studies have shown the dramatic potential of thorough initiation of medical treatment for HFrEF (β-blockers, angiotensin receptor– neprilysin inhibitors, mineralocorticoid-receptor villains and salt– glucose cotransporter 2 inhibitors) to decrease the risk of a combined end point of cardiovascular death or hospitalization for cardiac arrest over 70 percent when compared to historically approved cardiac arrest therapy.
In clients with HFrEF (EF less than 40 percent) with or without diabetes, dapagliflozin lowered cardiovascular deaths and heart failure hospitalizations when compared to a placebo. In addition, SGLT-2 inhibitors have actually been shown to decrease dangers of heart failure events in patients with Type 2 diabetes mellitus at high threat for or with cardiovascular disease.
© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this content? View our policies by click on this link.
More articles on cardiology: NYU Langone releases new pediatric cardiac arrest, transplant programUC San Diego Health 1st on West Coast to revive non-beating heart for transplantationPotential COVID-19 treatment might increase cardiac occasion risk if taken with certain drugs
Detailed analysis techniques are transforming our technique [around] simultaneous initiation of multiple medications for heart failure with lowered ejection portion (HFrEF). Considering that medications for HFrEF have actually been incrementally checked over ideal medical management, clinicians have been constrained and often confused by the requirement to include treatments one at a time.
For patients with heart failure associated to a weak point of their hearts capability to pump blood forward, the Accucinch device is being studied as a device to improve their hearts strength. It is a band put on the within of the heart to improve the heart into a shape that is more powerful.